Intermittent fasting (IF) has rapidly gained traction as a metabolic intervention in diabetes management. In their 2025 narrative review, Shyamala et al. synthesize emerging evidence from multiple clinical studies exploring various IF regimens—16/8, 5:2, and Eat-Stop-Eat—highlighting improvements in weight, insulin sensitivity, and glucose regulation, particularly in type 2 diabetes mellitus (T2DM). However, the review cautions against universal adoption due to risks of hypoglycemia and dehydration in insulin-dependent or type 1 diabetes mellitus (T1DM) patients.
The authors emphasize individualized medical supervision, real-time glucose monitoring, and medication titration as essential safeguards. As evidence evolves, IF may become a potent adjunct in holistic diabetes care—but only when clinically tailored. Read the full narrative review in the Journal of Family Medicine and Primary…
